Poland· PL-100106089
MultiHance
A gadobensäure product containing dimeglumini gadobenas, registered in Poland by Bracco Imaging Deutschland GmbH. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Gadobensäure is registered in 9 of 19 countries.
Countries holding a registration under ATC V08CA08 (gadobensäure), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Gadobensäure · ATC V08CA08
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Dimeglumini gadobenas
- Manufacturer
- Bracco Imaging Deutschland GmbH
- Country
- Poland (PL)
- ATC code
- V08CA08
- ATC class
- Gadobensäure
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990917440
- gtin05909990917419
- gtin05909990917426
- gtin05909990917433
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V08CA08
Gadobensäure, as other registers publish it.
- DenmarkMultiHanceBracco Imaging S.p.A.
- NorwayMultiHanceBracco Imaging SpA
- DenmarkMultiHanceBracco Imaging S.p.A.
- CzechiaMULTIHANCEBracco Imaging Deutschland GmbH, Konstanz
- CzechiaMULTIHANCEBracco Imaging Deutschland GmbH, Konstanz
- CzechiaMULTIHANCEBracco Imaging Deutschland GmbH, Konstanz
- CzechiaMULTIHANCEBracco Imaging Deutschland GmbH, Konstanz
- CzechiaMULTIHANCEBracco Imaging Deutschland GmbH, Konstanz
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c02e4a1c-4579-4e54-8c4f-d6a3e9e5104a GET /v1/drugs/c02e4a1c-4579-4e54-8c4f-d6a3e9e5104a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań dożylnych",
"source": "urpl",
"strength": "529 mg/ml (0,5 mmol/ml)",
"packaging": "05909990917419 ¦ Rp ¦ 18387\n1 fiol. 5 ml\n05909990917426 ¦ Rp ¦ 18388\n1 fiol. 10 ml\n05909990917433 ¦ Rp ¦ 18389\n1 fiol. 15 ml\n05909990917440 ¦ Rp ¦ 18390\n1 fiol. 20 ml",
"substance": "Dimeglumini gadobenas 529 mg",
"common_name": "Dimeglumini gadobenas",
"pl_product_id": "100106089",
"pozwolenie_nr": "09174",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about gadobensäure.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.